HEALTH AND WELLNESS
Phase 2a Trial for GlyphAgo™ Begins with First Patient - SPTX
Seaport Therapeutics has dosed its first patient in a Phase 2a trial for GlyphAgo™, targeting anxiety and sleep issues.
BOSTONGLYPH AGO™PURE TECHSEAPORT THERAPEUTICS
Coverage
0 articles No coverage is available.
Related
No related articles are available.